The PleuraFlow Catheter System is the lead product developed by Clear Catheter Systems.
Contact Clear Catheter Systems
To learn more about innovative surgical products from PleuraFlow Catheter Systems, complete the form below or call us at 541-382-8346.
Oregon Office:
2200 NE Neff, Suite 204
Bend Oregon 97701
Cleveland Office:
10265 Carnegie Avenue
Cleveland, Ohio 44108
Email: emb@clearcatheter.com
Phone: 541-382-8346
About Clear Catheter Systems
Clear Catheter Systems is a Bend, Oregon based medical device company pioneering new technologies that will revolutionize medical tube drainage. The company is developing its anti-clogging platform of surgical drainage devices. The company's lead product is the PleuraFlow Catheter. By solving the clogging problem the company's products will allow doctors to manage bleeding and clogging in large diameter chest tubes in a safer fashion. A further benefit is that surgeons will be able to utilize minimally invasive drainage tubes, resulting in a reduction in concern for clogging and increased patient comfort. The company has a pipeline of products based on its proprietary tube clearance technology to treat tube clogging in other medical market segments, including its system for the urinary catheter drainage market, and GastroFlow catheter system, for the enteral feeding market sector as well as systems for standard surgical drains. (www.clearcatheter.com)
Press, News and Updates:
October 22, 2009
October 18, 2009
PleuraFlow Clearance System Wins Prestigious EACTS 2009 Award
EACTS Daily News
Clear Catheter Systems Growing
Today's Medical Developments
January 12, 2009
Investor Update, January 2009 Newsletter
July 24, 2008
CCS raises $600,000 to further develop tube clearance system
Medical Device Daily
July 24, 2008
Oregon medical device company plans Cleveland office
Crain's Cleveland Business
July 24, 2008
Bend startup gets $600K investment
The Bulletin
July 24, 2008
Cleveland Clinic spinoff gets $600,000 from investors
Medical and Science New from the Plain Dealer
July 24, 2008
Clear Catheter Systems Completes $600,000 Financing, Opens Cleveland Office
February 12, 2008
Investor Update, February 2008 Newsletter
October 18, 2007
CLEVELAND CLINIC AND MEDICAL DEVICE INNOVATIONS, LLC, FORM CLEAR
CATHETER SOLUTIONS, LLC TO DEVELOP WOUND DRAINAGE SYSTEMS
October 18, 2007
Oregon incubator, Clinic form joint ventures
Board of Directors
Edward Boyle, MD
Chief Executive Officer, Clear Catheter Systems
Andrew Firlik, MD, Founder
Andrew Firlik is a neurosurgeon and venture capitalist, currently a general partner at Foundation Medical Partners.
Sam Kiderman, PhD
Director, New Ventures, Cleveland Clinic Innovations (CCI).
Tim Lynch
Mr. Lynch is a managing director of Stonepine Capital.
George Trutza
Mr. Trutza is currently the Entrepreneur in Residence for Cleveland Clinic Innovations.
Edward M. Boyle, Jr., MD
Chief Executive Officer, Clear Catheter Systems
emb@pleuraflow.com
541-390-1823
Dr. Boyle is a Cardiovascular and Thoracic Surgeon in Bend, Oregon. Dr. Boyle is board certified by the American Board of Surgery and the American Board of Thoracic Surgery, and a Fellow of the American College of Surgeons and the American College of Chest Physicians. He studied medicine at University of Minnesota Medical School, and trained in general surgery and cardiothoracic surgery at the University of Washington.
During his clinical training at the University of Washington, he led the Cardiovascular Vascular Biology research team where he developed basic science and clinical research programs, primarily focusing on the study of tissue injury, coagulation and inflammation. He has published over 75 manuscripts in peer reviewed medical journals and textbooks. In addition to obtaining NIH funding, he played the lead role in developing research collaborations with Bayer's Pharmaceutical Division, Genentech, Zymogenetics/Novo Nordisk, Icos Corporation, US Surgical Corporation (now Covidient Healthcare) and other privately held biotechnology and device companies. This research program was recognized nationally with awards from the American College of Surgeons, the American Heart Association, The Western Thoracic Surgery Association, the Seattle Surgical Society and others.
Dr. Boyle was a founder of Elixis, a healthcare information technology company which was acquired by Data Critical Corporation (NASDAQ: DCCA), now a division of General Electric (NYSE: GE). Dr. Boyle is the founder of Medical Device Innovations, Clear Catheter Systems and Precision Thoracic Corporation, early stage medical device companies where he is an inventor on a number of medical devices patent applications.
Andrew Firlik M.D., Founder
Andrew Firlik is a neurosurgeon and venture capitalist, currently a general partner at Foundation Medical Partners.
Dr. Firlik's career spans neurosurgery, entrepreneurship, and venture capital. He joined Foundation Medical Partners to concentrate on medical device and biopharmaceutical investments. Prior to Foundation, he was a venture partner at Sprout Group and Managing Director of its healthcare technology spinout, New Leaf Venture Partners. Previously, he was a principal at Canaan Partners. Dr. Firlik has led numerous venture capital investments and has served as a founder, founding investor, or director of many companies, including Northstar Neuroscience, NeuroVista, Sopherion Therapeutics, Transoma, Omnisonics, Marinus Pharmaceuticals, Viacor, and Spine Wave.
Dr. Firlik is a founder and an inventor of the core technology platform of Northstar Neuroscience (NASDAQ: NSTR), a medical device company that is pioneering a novel approach to neuromodulation for the treatment of stroke and other disorders. He is currently the Chairman of NovaVision, a medical therapeutics firm focusing on neuroplasticity for visual disorders. He also currently serves on the board of directors of several companies, including NeuroVista, Spine Wave, Clear Catheter Systems, Intelect Medical, BridgePoint Medical, Innovative Metabolics, and Visiogen. Dr. Firlik is a member of the Industrial Advisory Board of Cleveland Clinic Innovations Center and the Administrative Board of the Cornell University Council and Chairman of its Technology Transfer Committee.
Dr. Firlik spent 12 years in the healthcare profession during his medical training and practice as a neurological surgeon. He has published more than 50 articles in the medical literature, written chapters for several medical textbooks, and is the co-editor of a book about cerebrovascular surgery. His scientific work has been presented at many international conferences. He has been an inventor of numerous patents.
He studied biology at Cornell University and Oxford University, received his MBA from the University of Pittsburgh, and his MD from Cornell University Medical College. As a board certified neurosurgeon, Dr. Firlik most recently served as Clinical Assistant Professor of Neurosurgery at the New York University School of Medicine.
Sam Kiderman, Ph.D.
Director, New Ventures, Cleveland Clinic Innovations (CCI).
Dr. Kiderman's main focus is the administration, development and growth of new ventures/spin offs. Prior to joining CCI, he was responsible for Clinic Care, a subsidiary of the Cleveland Clinic, which provides multifunctional support for the Clinic and CCI spin-offs. Sam has extensive experience in business development and has been involved in the organization and start-up of a number of financially successful companies. He serves as a treasurer for PrognostiX and OrthoMEMS and serves on the board of directors of New Generation Technology and Foundation for Humanitarian Aid. Prior to the Cleveland Clinic, Sam had started-up and developed financially successful business enterprise and held executive financial positions with several organizations. He also served as a business Advisor/Consultant for several Foreign Embassies. Other industries of expertise include bio-tech, commercial real estate investments and financial services. His B.S. in Accounting, MBA and Ph.D. in Economics are from Moscow State University.
Tim Lynch
Mr. Lynch is a managing director of Stonepine Capital.
Since October 2005, Mr. Lynch has served as President and Chief Executive Officer of NeuroStat Pharmaceuticals, a specialty pharmaceutical company. From June 2005 through September 2005, Mr. Lynch was President and Chief Executive Officer of Vivo Therapeutics, a specialty pharmaceuticals company. From October 2002 through June 2005, Mr. Lynch served as Chief Financial Officer of Tercica, a publicly-traded biopharmaceutical company. From 1999 to June 2002, Mr. Lynch served as Chief Financial Officer of InterMune, a publicly-traded biopharmaceutical company. Currently, Mr. Lynch serves as a member of the board of directors of both Nabi Biopharmaceuticals, a publicly-traded biopharmaceutical company, and Allos Therapeutics, a publicly-traded biotechnology company, and BioForm Medical. Mr. Lynch holds a B.A. from Colgate University and an M.B.A. from the Harvard Graduate School of Business.
George Trutza
Mr. Trutza is currently the Entrepreneur in Residence for Cleveland Clinic Innovations.
Mr. Trutza has considerable experience in this market space, having served as President of the Kendall Medical & Surgical Division (now Covidien) and President of Tyco Healthcare Group Canada with annual sales of $600M and $150M respectively. He spent 11 years at US Surgical in a number of senior sales and marketing management roles. As Vice President of Marketing, George took over the Suture business driving it to over $200M in sales and successfully laid the foundation for the integration of the acquisition of Davis&Geck suture products. He left Tyco to join Surgicon Inc. a Connecticut based turnaround minimally invasive medical device company. From there he joined Accellent, Inc a medical device contract manufacturing company as EVP & GM of the companies Endo Division, and recently has been evaluating medical device opportunities and serving as an Executive in Residence at the Cleveland Clinic Innovation Center. Mr. Trutza accepted the offer to join the board and is actively advising the company on issues related to developing its product to the state where it will be feasible for them to be introduced clinically and marketed and sold worldwide.